Coronavirus company news summary – Datametrex secures rights to sell PCL’s Covid-19 antigen detection kits – QDX HealthID signs distribution agreement with Innova Medical Group

13 August 2020 (Last Updated August 13th, 2020 09:48)

Canada-based Datametrex has gained the rights to sell and distribute South Korean manufacturer PCL’s COV05 COVID19 Rapid Antigen Detection Kit. The kit is meant as a point of care test and does not require additional equipment. PCL maintain that it is easy to use and has over 97% accuracy. It provides results in 5 to 10 minutes.

Baxter International has secured emergency use authorisation (EUA) from the US FDA for its HF20 Set and ST Set used in continuous renal replacement therapy (CRRT). As per the EUA, the HF20 Set can be used to deliver CRRT to treat patients of low weight (8-20 kg) and low blood volume who cannot tolerate a larger extracorporeal circuit volume in an acute care environment during the Covid-19 pandemic. The ST Set can be used to provide CRRT to treat patients in an acute care environment during the Covid-19 pandemic. HF20 Set and ST Set can be used with the Prismaflex or PrisMax control units.

QDX HealthID, along its parent Quantum Materials, has signed a distribution agreement with Innova Medical Group, a wholly-owned subsidiary of Pasaca Capital, for the inclusion of IMG’s rapid-result antigen and antibody tests, and PCR swab tests, in the QDX HealthID ecosystem of Covid-19 testing solutions.

Quidel, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, has secured authorisation from the Health Canada to market and sell the Lyra Direct SARS-CoV-2 Assay in Canada. The Lyra reagents consist of features that enable simple transport and storage, improved workflow, shorter time to result besides other benefits.